| Patient 1 | Patient 2 | Patient 3 |
---|---|---|---|
Age | 62 | 59 | 58 |
Sex | Male | Female | Female |
Patient history | |||
 Pre-stroke mRS (0–5) | 0 | 0 | 0 |
 Comorbidities | Hypertension, prediabetic | Hypertension, Diabetic, Obesity | Hypertension, Obesity |
 Antiplatelet/anticoagulant | No | No | No |
COVID-19 characteristics | |||
 Nasopharyngeal swab | Positive | Positive | Positive |
 Chest X-ray | Viral pneumonia characteristics (bilateral) | Viral pneumonia characteristics (bilateral) | Viral pneumonia characteristics (bilateral) |
 Fever | No | Yes | No |
 Cough | Yes | No | No |
 Dyspnea | No | Yes | Yes |
 Myalgia | No | No | No |
 Gastrointestinal symptoms | No | No | No |
 Pharmacological treatment | Favipiravir, antibiotic therapy; Levofloxasin, Azithromycin and enoxoparin 40 mg once daily | Favipiravir, antibiotic therapy; Levofloxasin, Ceftriaxone and enoxoparin 40 mg once daily | Favipiravir, antibiotic therapy; Levofloxasin, Ceftriaxone. Enoxoparin (-) |
 IV tPA | Yes (80% of the total IV tPA dose) | Yes | Yes (80% of the total IV tPA dose) |
 Initial SpO2 (room air) | 90% | 80% | 93% |
 Oxygen therapy | Nasal Cannule | NRB | NRB |
Laboratory findings | |||
 Haemaglobin, g/dl | 15.4 | 11 | 13.8 |
 Leucocyte × 109/L | 7.7 | 10.2↑ | 11.8↑ |
 Platelets × 109/L | 538↑ | 516↑ | 314 |
 Neutrophils, % | 71↑ | 89↑ | 78↑ |
 Lymphocytes, % | 12↓ | 6↓ | 15↓ |
 aPTT, s | 26 | 27 | 28.1 |
 PT, s | 13.4 | 13.8 | 13.4 |
 INR | 0.94 | 0.97 | 0.92 |
 Fibrinogen, mg/dl | 473↑ | 655↑ | 423↑ |
 D-dimer, ng/ml | 1710↑ | > 20,000↑ | 910↑ |
 AST, U/L | 31 | 13 | 15 |
 ALT, U/L | 58↑ | 18 | 9 |
 Creatinine, mg/dl | – | 0,4 | 0.8 |
 Glucose, mg/dl | 168↑ | 410↑ | 140 |
 LDH, U/L | – | 813↑ | – |
 CRP, mg/dl | 0.7 | 8.3↑ | 2.9↑ |
Stroke features | |||
 Clinical symptoms | Right hemiparesis, aphasia | Left hemiparesis, dysarthria | Right hemiparesis,dysarthria |
 NIHSS at baseline | 12 | 10 | 10 |
 NIHSS after 24 h | 4 | 6 | Not available |
 Haemorrhagic transformation | No | No | Yes (Intraventricular haemorrhagic) |
 Complication | None | Respiratory insufficiency (ARDS) | Respiratory insufficiency (ARDS) |
 Outcome | Clinical recovery | Death | Death |